Artwork

Kandungan disediakan oleh The Motley Fool. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh The Motley Fool atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

A New Name in Weight-Loss Drugs

26:21
 
Kongsi
 

Manage episode 419277122 series 3329
Kandungan disediakan oleh The Motley Fool. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh The Motley Fool atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Novo Nordisk and Eli Lilly have soared on GLP-1 weight-loss drugs – now Hims & Hers is trying to get in on the action with a more available and affordable option.

(00:21) Asit Sharma and Dylan Lewis discuss:

- Hims & Hers getting into the business of GLP-1 weight loss injections and what the compound market means for Novo Nordisk and Eli Lilly.

- A sneaky company that’s another winner in the weight-loss market.

- Wix’s successful pivot to a free-cash-flow orientation, and how the AI wave is pushing the company forward.

(14:52) Gym stocks haven’t worked out for most investors, Ricky Mulvey caught up with Motley Fool analyst Sanmeet Deo to find out why he has cooled on one fast-growing gym franchisor and a space in fitness that is investable.

Companies discussed: HIMS, NVO, MCK, LLY, Wix

Host: Dylan Lewis

Guests: Asit Sharma, Ricky Mulvey, Mary Long

Producer: Ricky Mulvey

Engineers: Dan Boyd

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1592 episod

Artwork

A New Name in Weight-Loss Drugs

Motley Fool Money

593 subscribers

published

iconKongsi
 
Manage episode 419277122 series 3329
Kandungan disediakan oleh The Motley Fool. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh The Motley Fool atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Novo Nordisk and Eli Lilly have soared on GLP-1 weight-loss drugs – now Hims & Hers is trying to get in on the action with a more available and affordable option.

(00:21) Asit Sharma and Dylan Lewis discuss:

- Hims & Hers getting into the business of GLP-1 weight loss injections and what the compound market means for Novo Nordisk and Eli Lilly.

- A sneaky company that’s another winner in the weight-loss market.

- Wix’s successful pivot to a free-cash-flow orientation, and how the AI wave is pushing the company forward.

(14:52) Gym stocks haven’t worked out for most investors, Ricky Mulvey caught up with Motley Fool analyst Sanmeet Deo to find out why he has cooled on one fast-growing gym franchisor and a space in fitness that is investable.

Companies discussed: HIMS, NVO, MCK, LLY, Wix

Host: Dylan Lewis

Guests: Asit Sharma, Ricky Mulvey, Mary Long

Producer: Ricky Mulvey

Engineers: Dan Boyd

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1592 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas